Halozyme Therapeutics Rating Reiterated by Barclays (HALO)
Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “equal weight” rating reiterated by stock analysts at Barclays in a report issued on Friday, AmericanBankingNews.com reports. They currently have a $15.00 target price on the stock, up from their previous target price of $12.00. Barclays’ price objective would suggest a potential downside of 7.12% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at BMO Capital Markets raised their price target on shares of Halozyme Therapeutics from $13.00 to $17.00 in a research note to investors on Monday, November 11th. Analysts at UBS AG raised their price target on shares of Halozyme Therapeutics from $8.00 to $14.00 in a research note to investors on Monday, November 11th. They now have a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $11.14.
Shares of Halozyme Therapeutics (NASDAQ:HALO) opened at 16.15 on Friday. Halozyme Therapeutics has a one year low of $5.03 and a one year high of $16.45. The stock has a 50-day moving average of $14.57 and a 200-day moving average of $10.66. The company’s market cap is $1.821 billion.
Halozyme Therapeutics (NASDAQ:HALO) last released its earnings data on Friday, November 8th. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.15) by $0.02. The company had revenue of $16.00 million for the quarter, compared to the consensus estimate of $14.62 million. During the same quarter last year, the company posted ($0.18) earnings per share. Halozyme Therapeutics’s revenue was up 200.2% compared to the same quarter last year. On average, analysts predict that Halozyme Therapeutics will post $-0.71 earnings per share for the current fiscal year.
Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.